AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01255904 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral placebo
Description: Oral saline administered
Study NCT01255904 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intranasal placebo
Description: Intranasal saline administered
Study NCT02154932 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2 doses 400 microgram misoprostol
Description: 2 doses 400 microgram misoprostol, 3 and 1 hours
Study NCT02154932 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: single dose misoprostol
Description: 1 dose, 1 hours, prior surgery
Study NCT04192721 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy-Based Group Counseling
Description: * Relaxation techniques~* Providing personal development books~* Sharing the factors affecting the situation defined as depression (brainstorming)~* Explaining the link between depressive symptoms, thoughts, feelings, and behaviors~* Explaining automatic thoughts~* Application of relaxation techniques; deep-breathing exercises~* Identifying alternative thoughts~* Explaining the correlation between alternative thoughts and mood~* Introduction of the Automatic-Thought Registration Form and distribution to students~* Describing the effects of depression on social interaction~* Explaining activities that could be done individually and with the group~* Distribution of the activity list to students~* Description of ways of coping with stress~* Determination of individual stressors and their effects~* Planning for the future: preventing depression~* Discussion of assumptions/expectations about life~* Homeworks related to session contents
Study NCT03607877 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pedometer walking training and positive education
Description: Intervention: (1)Positive education: Six psychosocial sessions were designed to enhance elders' positive emotion, motivation and self-efficacy to walk.~(2) Pedometer walking training: walk at least 30 minutes per day and at least three times per week with family support and exercise companions.
Study NCT03607877 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pedometer walking with training
Description: Intervention:walk at least 30 minutes per day and at least three times per week with family support and exercise companions.
Study NCT03607877 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: pedometer walking
Description: Intervention: pedometer walking at least 30 minutes per day and at least three times per week
Study NCT01214889 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PENTAXIM™: DTacP IPV//PRP~T combined vaccine
Description: 0.5 mL, intramuscular
Study NCT01214889 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TETRAXIM™: DTacP IPV combined vaccine and ActHIB™: PRP tetanus conjugate vaccine
Description: 0.5 mL of each vaccine; intramuscular
Study NCT01997034 — intervention group
Intervention type: BEHAVIORAL
Intervention: Intensive Lifestyle Intervention
Description: The included subjects has previously participated in the Intensive Lifestyle Intervention intervention at Ubberup Folk High School. This intervention includes daily exercise and a hypocaloric diet (app. -700KCal/day) for 10-14 weeks. Furthermore theoretical and practical education within e.g. Nutrition, exercise and motivational psychology.
Study NCT03793569 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer discussion group
Description: Subjects in the intervention group will be asked to attend one peer group between four and eight weeks postpartum. Peer groups will be expected to last approximately one hour. Each peer group will include 5-10 new mothers. A facilitator will be present for these groups, but the hope is to have mothers discuss with each other their postpartum experience and activities of their newborn at home.
Study NCT00735345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 750 mg/m2/d C.I. i.v.d1-5, d29-33 and 300 mg/m2/d C.I. i.v. on the days of radiotherapy
Study NCT02946853 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy - defibrillator
Description: Insertion of device capable of providing biventricular pacing and cardiac defibrillation
Study NCT00735345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 15 mg/m2/d i.v. d1-5, d29-33
Study NCT00735345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxotere
Description: 75 mg/m2/d i.v. d1 and d29, 15 mg/m2/d i.v. on d57, d64, d71 and d78
Study NCT00735345 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab: 400 mg/m2 i.v. d1; 250mg/m2 weekly d8 through d85
Study NCT00735345 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation during chemoradio-immunotherapy
Description: 39.6 Gy total dose
Study NCT01759953 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Game
Description: InsuOnline game, on the web, in the player´s own time and rhythm
Study NCT01759953 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional CME
Description: In-classroom traditional learning session about insulin therapy for diabetes, using a presential short lecture and a group discussion of the same clinical cases presented in the InsuOnline game
Study NCT01571960 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEO-D03 DNA vaccine
Description: Either a 0.3-mg (Group 1: study vaccine) or 3-mg dose (Groups 2 and 3: study vaccine) administered as a 1-mL IM injection into the deltoid
Study NCT01571960 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA/HIV62B (MVA62B) vaccine
Description: 1 x 10\^8-TCID50 dose of MVA62B vaccine, administered as a 1-mL IM injection into the deltoid
Study NCT01571960 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for GEO-D03 DNA
Description: Administered as a 1-mL IM injection into the deltoid
Study NCT01571960 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for MVA62B:
Description: Administered as a 1-mL IM injection into the deltoid
Study NCT03789331 — intervention group
Intervention type: OTHER
Intervention: Anogenital distance measurement
Description: The women were kindly asked to lay down in the lithotomy position with their thighs at 45° to the examination table. A digital caliper (Mitutoyo 500-752-10 ABSOLUTE Digimatic Coolant Proof Caliper 0-150mm / 0-6, Mitutoyo Corporation, Japan) was used to measure anogenital distance.~Anogenital distance anus to clitoris: will be measured in centimeters from the anterior clitoral surface to the center of the anus.~Anogenital distance anus to fourchette: will be measured in centimeters from the posterior fourchette to the center of the anus.~Two investigators who were blind to the gynecological status of the women will measure each distance three times, and the mean value of the six measurements of each anogenital distance will be used.
Study NCT01653054 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anal Pap Smear, HPV DNA Testing
Description: Anal Pap Smears and HPV DNA testing will be performed on all subjects.
Study NCT05538026 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesalazine
Description: daily dose of 3 g (2 g orally + 1 g rectally)
Study NCT05538026 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal transplantation
Description: Preparation of fresh feces by blending in 0.9 % saline and crude filtering. The solution is applied in proximal colon of UC patient by colonoscopy after standard bowel preparation.
Study NCT02795364 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Structural Image Guidance
Description: Resecting the tumor in accordance with the margin on MRI T1W-enhanced delineation
Study NCT02795364 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Metabolic Image Guidance
Description: Aggressive resecting of the tumor in accordance with the margin on MRS CNI delineation
Study NCT03332043 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HIRREM
Description: HIRREM (Brain State Technologies, Scottsdale, AZ) is a closed-loop, allostatic, acoustic stimulation neurotechnology that uses software-guided algorithmic analysis to identify and translate selected brain frequencies into audible tones of varying pitch and timing, to support real-time self-optimization of brain activity.
Study NCT03332043 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ambient Nature Sounds
Description: Digitally recordings of various ambient nature sounds such as a stream, waterfall, ocean waves, or rainfall, are provided via ear buds.
Study NCT02906436 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xvivo Chamber
Study NCT00588692 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: SphygmoCor
Description: The SphygmoCor, a hand-held tonometer will assess central blood pressure noninvasively. This pencil-like device is applied over the radial artery, and uses a validated mathematical transformation to derive central aortic pressure.
Study NCT00588692 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SphygmoCor
Description: The SphygmoCor, a hand-held tonometer will assess central blood pressure noninvasively. This pencil-like device is applied over the radial artery, and uses a validated mathematical transformation to derive central aortic pressure.
Study NCT02799563 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coach, Preselected number of cases
Study NCT02799563 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coach, Self-selected number of cases
Study NCT02799563 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No coach, Preselected number of cases
Study NCT02799563 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No coach, Self-selected number of cases
Study NCT02651870 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Candesartan 16mg
Study NCT02651870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan 16mg
Study NCT02651870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine 5mg
Study NCT02651870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine 10mg
Study NCT02486692 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AboutFace Website
Description: AboutFace is an informational website that utilizes digital storytelling to describe PTSD symptoms and different treatments for PTSD.
Study NCT01906242 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: water
Study NCT01906242 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sodium hypochlorite
Study NCT01906242 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sodium bicarbonate
Study NCT01906242 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: chlorhexidine
Study NCT00480090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Initially given at 1g/m2 bid for 2 days every 3 weeks over 2 hours. The dose will be escalated: level 1 - 1.25g/m2, level 2, 1.5g/m2.
Study NCT00877318 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SCAD information system
Description: Cardiac rehabilitation at home by telemedicine
Study NCT03276650 — intervention group
Intervention type: OTHER
Intervention: data collection
Description: biological, administrative, clinical, outcome date
Study NCT02995759 — intervention group
Intervention type: OTHER
Intervention: Seizure Action Plan
Description: The action plan will be electronically formatted in the EMR. After electronic creation, the primary neurologist and patient/caregiver will create a patient-specific plan.
Study NCT00484029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasal Carbon Dioxide
Description: Nasal Carbon Dioxide
Study NCT00484029 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Air
Description: Air (Medical Grade)
Study NCT02466464 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Microporous Polysaccharide Hemospheres
Description: Two grams of Arista powder will be placed into the nose followed by four minutes of pressure and a moustache dressing.
Study NCT04956471 — intervention group
Intervention type: OTHER
Intervention: interview
Description: A sample method: convenience sampling, selecting A 3 armour hospital between September 2019 and January 2020 neurology hospital patients with swallowing disorder after stroke, about 15 cases.
Study NCT02466464 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal Tampon
Description: 8 cm of Merocel dressing will be placed into one or both sides of your nose for the next three to five days and will then be removed by the physician.
Study NCT02668965 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intrauterine hCG (pregnyl)
Study NCT00057291 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Responsive caregiving
Description: Responsive caregiving consisted of operational circumstances and training of caregivers.
Study NCT00129441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Merck L-830982
Description: The initial dose of L-830982 was 3.0 mg twice daily (b.i.d.) the dosage increased to 5.0 mg b.i.d. at the end of week 1 and 8.0 mg b.i.d. at the end of week 2, which was continued for the remaining 2 weeks of the trial. Medications were dispensed weekly in blister packs by the hospital pharmacy.
Study NCT00129441 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Medications were dispensed weekly in blister packs by the hospital pharmacy, using the same number of pills as those on active drug.
Study NCT01716806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: 1.8 mg/kg every 3 weeks by IV infusion
Study NCT01716806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bendamustine
Description: 70 mg/m\^2 by IV infusion on Days 1 and 2 of 3-week cycle
Study NCT01716806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dacarbazine
Description: 375 mg/m\^2 every 3 weeks by IV infusion
Study NCT01716806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: 3 mg/kg every 3 weeks by IV infusion
Study NCT01893112 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unity Workshop
Description: The intervention is based on other stigma reduction programs that are being used internationally (HIV Stigma Toolkit developed by the International Center for Research on Women and trigger videos developed by International Training \& Education Center for health).
Study NCT01893112 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Breast Cancer Screening
Study NCT00508950 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Large volume blood draw
Description: Large volume blood draw
Study NCT00938353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: beclomethasone dipropionate suspension for nebulisation 800 mcg/2 ml
Description: Single dose 1600 mcg/4 ml
Study NCT05653102 — intervention group
Intervention type: DEVICE
Intervention: Truliant Total Knee System
Description: Total Knee Arthroplasty using Exactech's Truliant® branded components are compatible with Optetrak branded components.
Study NCT00938353 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo solution for nebulisation 2 ml
Description: single dose: 4 ml
Study NCT02155192 — intervention group
Intervention type: DRUG
Intervention: No Intervention
Study NCT00667563 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine
Description: Vaccination with the Quadrivalent Human Papillomavirus Recombinant vaccine (0.5 mL Gardasil®) by intramuscular (IM) injection at Day 0, Weeks 8 and 24.
Study NCT00667563 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DNA analysis
Description: Weeks 0, 2, 10, 26, and 52.
Study NCT00667563 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymerase chain reaction
Description: Screening, week 36, and week 52.
Study NCT00667563 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cytology specimen collection procedure
Description: Screening, week 36, and week 52.
Study NCT00667563 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: colposcopic biopsy
Description: Screening, week 36, and week 52.
Study NCT03370744 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropsychological scale
Description: Neuropsychological scale, including mini-mental state examination (MMSE), Montreal cognitive assessment (MoCA), clinical dementia rating scales (CDR) and so on
Study NCT03159936 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tofacitinib citrate
Description: 10 mg daily by mouth
Study NCT00356447 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol/DRSP (Angeliq, BAY86-4891)
Description: Drospirenone (DRSP) 2mg and Estradiol 1mg. One cycle consists of 28 days. One tablet daily for 28 days given for a total of 4 cycles. Oral administration.
Study NCT00356447 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Same administration.
Study NCT00692380 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fractionated radiation therapy followed by chemotherapy
Description: Increasing doses of radiation therapy
Study NCT04348526 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Corticision
Description: Surgical intervention is going to be used in the interdental areas between the lower anterior teeth to accelerate tooth movement. Three incisions are going to be made
Study NCT04348526 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional orthodontic treatment
Description: No surgical intervention will be used, just normal orthodontic sequence of procedures.
Study NCT04088669 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based Pulmonary Rehabilitation
Description: Patients will admit a home-based pulmonary rehabilitation program for 8 weeks, with a minimum of 3 days per week and one session of this is under the supervision of a physiotherapist. The pulmonary rehabilitation program includes stretching exercises, strengthening exercises for upper and lower extremities, breathing exercises and aerobic exercises (walking). All of these exercises will be equipped with equipment that the patients can easily provide at home. In addition, patients will be provided with a pedometer and exercise diary.
Study NCT04088669 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education and Recommendations
Description: The control group will be given a training session on the course of the disease and the correct inhaler use and will be given booklets on breathing exercises, aerobic exercises (walking) and physical activity recommendations for a minimum of 2-3 days per week for 8 weeks. Patients will be given a pedometer and exercise diary.
Study NCT02581683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: Given via adductor canal block
Study NCT02581683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Given via adductor canal block
Study NCT02581683 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Given via adductor canal block
Study NCT02581683 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham adductor canal block
Study NCT02191488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-aminolevulinic acid
Study NCT01950299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra 100 mg
Description: Anakinra 100 mg starting immediately and then every 24 hours
Study NCT01950299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra 100 mg
Description: Anakinra 100 mg starting 12 hours after first dose and then every 24 hours (so that Anakinra is given every 12 hours)
Study NCT01950299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo 0.67 ml injections twice daily
Study NCT01950299 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 0.67 ml injections twice daily
Study NCT03946059 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iTBS then cTBS
Description: repetitive transcranial magnetic stimulation applied with intermittent theta-burst stimulation protocol applied in week 1 and continuous theta-burst stimulation protocol applied in week 2.
Study NCT03946059 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cTBS then iTBS
Description: repetitive transcranial magnetic stimulation applied with continuous theta-burst stimulation protocol applied in week 1 and intermittent theta-burst stimulation protocol applied in week 2.
Study NCT01960101 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LactoXeros
Study NCT01960101 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Aequasyal
Study NCT03001947 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: Registration of all IgAN patients in the First Affiliated Hospital of Sun Yat-sen University and other hospitals which have signed the contract in China.
Study NCT04567940 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ENRED@TE: Behavioural multicomponent intervention
Description: Information and awareness activities; activities for the acquisition of skills; activities that help the elderly to attend spaces for leisure, participation and maintenance and/or improvement of their personal relationships.